Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 4

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 4
---

supplement and the accompanying prospectus or of any of our securities. Our business, financial condition, results of operations and prospects
may have changed since those dates.

In this prospectus supplement,
“we,” “us,” “our,” the “Company” and “Clearmind” refer to Clearmind Medicine
Inc. All trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience,
the trademarks and trade names in this prospectus supplement are referred to without the ® and ™ symbols, but such references
should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with,
or endorsement or sponsorship of us by, any other companies.

As of November 1, 2022, our
reporting currency and functional currency is the United States Dollar. Prior to that, our reporting currency and functional currency
was the Canadian Dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to “CAD$”
are to Canadian Dollars. Amounts denominated in United States Dollars are states as “$” “dollars” or “USD”.
Where previously disclosed financial information was in Canadian Dollars, we have included a convenience translation. This prospectus
supplement includes statistical, market and industry data and forecasts which we obtained from publicly available information and independent
industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally
state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness
of the information. We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board, or the IASB. None of the financial statements were prepared in accordance with generally accepted accounting principles in
the United States.

On September 30, 2022, we
effected a one-for-30 consolidation of our issued and outstanding Common Shares. In addition, on November 28, 2023, we effected a one-for-30
consolidation of our issued and outstanding Common Shares. Except where otherwise indicated, all share and per share data in this prospectus
supplement have been retroactively restated to reflect the aforementioned consolidations.

<div align='center'>S-ii

PROSPECTUS SUPPLEMENT SUMMARY